Transdiagnostic Behavioral Therapy for Anxiety and Depression in Autistic Adolescents

Last updated: July 18, 2025
Sponsor: Baylor College of Medicine
Overall Status: Completed

Phase

N/A

Condition

Depression

Anxiety Disorders

Panic Disorders

Treatment

Treatment as usual

Transdiagnostic cognitive behavioral therapy (CBT)

Clinical Study ID

NCT05738967
H-52639
  • Ages 12-17
  • All Genders

Study Summary

This study tests the effectiveness of a transdiagnostic cognitive behavioral therapy for autistic youth with anxiety and/or depression.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Child is between the ages of 12-17 at consent/assent.

  • The child meets criteria for autism spectrum disorder using evidence-basedassessment approaches (e.g., Autism Diagnostic Observation Schedule-Second Edition;Childhood Autism Rating Scale-Second Edition).

  • The child meets criteria for clinically significant anxiety and/or depressionsymptoms based on elevated scores on the Pediatric Anxiety Rating Scale modified forAutism Spectrum Disorder (>11) and/or the Children's Depression Rating Scale-Revised (>39).

  • Anxiety/depressive disorder is the primary presenting problem as determined byadministration of the Mini International Neuropsychiatric Interview

  • One parent/guardian is able and willing to participate.

  • The parent/guardian is 18 years or older.

  • Both parent and child can read and/or understand English.

  • Both parent and child reside in Texas.

Exclusion

Exclusion Criteria:

  • The child has a diagnosis of psychotic disorder and/or conduct disorder.

  • The child has severe suicidal/homicidal ideation and/or self-injury requiringimmediate intervention and/or a higher level of care.

  • The child has limited verbal communication abilities.

  • The child is receiving concurrent psychotherapy for anxiety/depression.

  • The child has initiated psychotropic medications within 12 weeks of assessments (or 4 weeks for stimulants/benzodiazepines) or during therapy, and/or has changed dosageof psychotropic medication within 6 weeks of assessment (or 2 weeks forstimulants/benzodiazepines) or during therapy.

Study Design

Total Participants: 47
Treatment Group(s): 2
Primary Treatment: Treatment as usual
Phase:
Study Start date:
March 15, 2023
Estimated Completion Date:
May 31, 2025

Study Description

About 1 in 54 adolescents are estimated to be on the autism spectrum, with over half suffering from anxiety or depressive disorders. These disorders contribute to suicidality, family stress, social impairments, and difficulties transitioning to adulthood among autistic youth. Given the frequency of anxiety and depressive disorders among autistic adolescents and the increased risk of impairment, developing effective treatments for anxiety and depression tailored to this population is a top priority.

Transdiagnostic cognitive behavioral therapy (CBT) for other populations, including typically developing adolescents, may confer broader benefits than disorder-specific CBT and facilitate broader dissemination and implementation. However, there has been little research conducted on transdiagnostic treatments among autistic adolescents. Thus, this study proposes to address this gap by testing transdiagnostic CBT for autistic adolescents with anxiety and depression.

The study involves two phases: 1) a pilot intervention; and 2) a randomized controlled trial.

The pilot intervention will involve 12 adolescent-caregiver dyads to further refine the treatment model and its assessment measures. The randomized trial will involve 100 adolescent-caregiver dyads to further evaluate the clinical efficacy of the treatment.

Connect with a study center

  • Baylor Psychiatry Clinic

    Houston, Texas 77030
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.